Quest Diagnostics Tests Positive For Value, Negative For Growth [View article]
As stated in a recent web cast, DGX growth will be impacted by the rollout of new diagnostic tests... and new paradigms of testing.
We are not anywhere close the "wellness chip" stage however there has and will continue to be significant diagnostic developments for the early detection of diseases including many cancer. The efficacy / cost-effectiveness thresholds to justifiy wider population screening will also soon be passed.
In the US, health plans will prefer the use of accuracte, relatively cheap diagnostic tests as a standard of care benchmark. Demand for esoteric testing and companion diagnostic processes can also be expected to increase over time, particularly given the aging of populations in the developed world.
A first challenge for Quest is to take the bull by the horns on all of this, including with the delivery of some new gold standard tests that have wide clinical application.
At a whole of industry level, global linkages between bigpharma, smallpharma and academia require urgent reexamination for the purpose of kick starting many more pipelines in a cost effective manner.
Quest Diagnostics Tests Positive For Value, Negative For Growth [View article]
We are not anywhere close the "wellness chip" stage however there has and will continue to be significant diagnostic developments for the early detection of diseases including many cancer. The efficacy / cost-effectiveness thresholds to justifiy wider population screening will also soon be passed.
In the US, health plans will prefer the use of accuracte, relatively cheap diagnostic tests as a standard of care benchmark. Demand for esoteric testing and companion diagnostic processes can also be expected to increase over time, particularly given the aging of populations in the developed world.
A first challenge for Quest is to take the bull by the horns on all of this, including with the delivery of some new gold standard tests that have wide clinical application.
At a whole of industry level, global linkages between bigpharma, smallpharma and academia require urgent reexamination for the purpose of kick starting many more pipelines in a cost effective manner.
Cellmid Granted Key Midkine Patent In U.S. For Heart Attack Program [View instapost]